Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Searle/Pfizer Celebrex

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Enrollment begins for a three-year study in more than 1,000 patients to test safety and efficacy of celecoxib in reducing the occurrence of new, sporadic adenomatous polyps in the colon and rectum in patients with at least one previously removed polyp. The multicenter, randomized, double-blind, placebo-controlled trial will test patients with a history of, but not a familial disposition toward, adenomatous polyps, which "are a precursor to more than 95 percent of all colorectal cancers," according to the companies. In December, the COX-2 inhibitor was approved for treatment of patients with familial adenomatous polyposis. Celebrex also is indicated for use in osteoarthritis and rheumatoid arthritis

You may also be interested in...

Improve Access to RWD In Asia To Make RWE Viable

Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.

Inflexion Outlines Rosemont Investment And Eyes More Generics Deals

In an exclusive interview with Generics Bulletin, Inflexion’s Ben Long reveals his ambitions for newly-acquired UK-based liquids generics specialist Rosemont Pharmaceuticals, including to drive investment in R&D and expand the company’s international footprint.

UK CBD Industry Welcomes FSA Clarification On Novel Food Evidence Requirement

“With so little publicly available information on the safety of CBD we anticipate that directly relevant studies will be needed,” explains the UK Food Standards Agency, in response to confusion within the country's CBD industry. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts